1. Home
  2. MREO vs ISD Comparison

MREO vs ISD Comparison

Compare MREO & ISD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • ISD
  • Stock Information
  • Founded
  • MREO 2015
  • ISD 2012
  • Country
  • MREO United Kingdom
  • ISD United States
  • Employees
  • MREO N/A
  • ISD N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • ISD Trusts Except Educational Religious and Charitable
  • Sector
  • MREO Health Care
  • ISD Finance
  • Exchange
  • MREO Nasdaq
  • ISD Nasdaq
  • Market Cap
  • MREO 438.8M
  • ISD 472.3M
  • IPO Year
  • MREO N/A
  • ISD N/A
  • Fundamental
  • Price
  • MREO $1.76
  • ISD $14.19
  • Analyst Decision
  • MREO Strong Buy
  • ISD
  • Analyst Count
  • MREO 5
  • ISD 0
  • Target Price
  • MREO $7.20
  • ISD N/A
  • AVG Volume (30 Days)
  • MREO 4.4M
  • ISD 127.1K
  • Earning Date
  • MREO 08-12-2025
  • ISD 01-01-0001
  • Dividend Yield
  • MREO N/A
  • ISD 9.69%
  • EPS Growth
  • MREO N/A
  • ISD N/A
  • EPS
  • MREO N/A
  • ISD N/A
  • Revenue
  • MREO N/A
  • ISD N/A
  • Revenue This Year
  • MREO N/A
  • ISD N/A
  • Revenue Next Year
  • MREO $51.92
  • ISD N/A
  • P/E Ratio
  • MREO N/A
  • ISD N/A
  • Revenue Growth
  • MREO N/A
  • ISD N/A
  • 52 Week Low
  • MREO $1.57
  • ISD $10.98
  • 52 Week High
  • MREO $5.02
  • ISD $13.17
  • Technical
  • Relative Strength Index (RSI)
  • MREO 35.35
  • ISD 59.49
  • Support Level
  • MREO $1.65
  • ISD $14.01
  • Resistance Level
  • MREO $1.89
  • ISD $14.14
  • Average True Range (ATR)
  • MREO 0.15
  • ISD 0.10
  • MACD
  • MREO -0.03
  • ISD -0.02
  • Stochastic Oscillator
  • MREO 12.84
  • ISD 63.33

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About ISD PGIM High Yield Bond Fund Inc.

PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The Fund's investment objective is to provide a high level of current income. It invests at least 80% of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.

Share on Social Networks: